MedTrace Logo

Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine

NCT04019184 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-05-21

No results posted yet for this study

Summary

The aim of this study is to evaluate whether the application of glutamine versus control in patients with high risk for AKI identified by biomarkers can reduce kidney damage after cardiac surgery.

Conditions

Interventions

DRUG

L-Alanyl/L-Glutamine

Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug

DRUG

Placebo

Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo

Sponsors & Collaborators

  • Fresenius Kabi

    collaborator INDUSTRY

  • IZKF (Interdisciplinary Centre for Clinical Research (IZKF), Muenster)

    collaborator UNKNOWN

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Alexander Zarbock, MD, PhD · University Hospital Muenster, Dept. of Anesthesiology, Intensive Care and Pain Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-18
Primary Completion
2020-02-13
Completion
2020-05-13

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04019184 on ClinicalTrials.gov